Banco de Sabadell’s Lineage Cell Therapeutics LCTX Stock Holding History

Banco de Sabadell’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,000	Closed	-$18K	–	368
2020 Q2	$18K	Hold	20,000	–	–	﹤0.01%	286
2020 Q1	$16K	Hold	20,000	–	–	﹤0.01%	299
2019 Q4	$17K	Hold	20,000	–	–	﹤0.01%	313
2019 Q3	$20K	Hold	20,000	–	–	﹤0.01%	320
2019 Q2	$22K	Buy	+20,000	New	+$23K	﹤0.01%	342
2019 Q1	–	Sell	-20,000	Closed	-$19K	–	392
2018 Q4	$19K	Sell	20,000 -2,860	-13%	-$4.38K	﹤0.01%	383
2018 Q3	$47K	Hold	22,860	–	–	0.01%	384
2018 Q2	$41K	Hold	22,860	–	–	0.01%	390
2018 Q1	$49K	Hold	22,860	–	–	0.01%	384
2017 Q4	$43K	Buy	+22,860	New	+$49.9K	0.01%	272

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Banco de Sabadell's LCTX Position: Q3 2020 in Review

Banco de Sabadell sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 20,000 shares — an estimated $18K sold.

Banco de Sabadell first reported a position in LCTX in Q4 2017 and held it in 10 quarters. The position peaked at $49K in Q1 2018. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

Banco de Sabadell reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
Banco de Sabadell sold 20,000 Lineage Cell Therapeutics shares in Q3 2020, an estimated $18K.
Banco de Sabadell first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 10 quarters.
Banco de Sabadell's Lineage Cell Therapeutics position peaked at $49K in Q1 2018.
75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Banco de Sabadell's 13F filing for Q3 2020, filed 13 Nov 2020.